BioMed Valley Discoveries

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, BioMed Valley Discoveries sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 4 completed early-phase tilt top decile by trial count

BioMed Valley Discoveries: 9 sponsored US clinical trials, none currently recruiting.

BioMed Valley Discoveries sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors, with 1 trials.

Top-decile sponsor footprint

BioMed Valley Discoveries ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

TERMINATED Phase 2

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

NCT05221320
TERMINATED Phase 2

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

NCT04488003
COMPLETED Phase 1

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

NCT02296242
COMPLETED Phase 1

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01924689
TERMINATED Phase 2

[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection

NCT01764919
COMPLETED Phase 1

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

NCT01781429
TERMINATED Phase 2

[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint

NCT01705496
TERMINATED Phase 1

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01118819
COMPLETED Phase 1

Biodistribution and Dosimetry Evaluation of [124I]FIAU

NCT01337466

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4

Therapeutic Areas

Advanced Solid Tumors 1

How the BioMed Valley Discoveries early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 4 completed (44%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumors (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

BioMed Valley Discoveries: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

BioMed Valley Discoveries sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share BioMed Valley Discoveries4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
BioMed Valley Discoveries sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

BioMed Valley Discoveries sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this BioMed Valley Discoveries page

9 registered trials is a research-attention snapshot, not an endorsement of BioMed Valley Discoveries or any single study.

  • None of BioMed Valley Discoveries's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Advanced Solid Tumors is the condition BioMed Valley Discoveries studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

BioMed Valley Discoveries pipeline card: 9 registered trials from official public datasets.Report a data error.